Cargando…

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells()

Two cellular proteins encoded by the breast and ovarian cancer type 1 susceptibility (BRCA1 and BRCA2) tumor suppressor genes are essential for DNA integrity and the maintenance of genomic stability. Approximately 5–10% of breast and ovarian cancers result from inherited alterations or mutations in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Węsierska-Gądek, Józefa, Zulehner, Nora, Ferk, Franziska, Składanowski, Andrzej, Komina, Oxana, Maurer, Margarita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494830/ https://www.ncbi.nlm.nih.gov/pubmed/22906755 http://dx.doi.org/10.1016/j.bcp.2012.07.024

Ejemplares similares

Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities
por: Lemke, Krzysztof, et al.
Publicado: (2005)

Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells
por: Węsierska-Gądek, Józefa, et al.
Publicado: (2014)

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging
por: Węsierska-Gądek, Józefa
Publicado: (2010)

Phenol red in the culture medium strongly affects the susceptibility of human MCF-7 cells to roscovitine
por: Węsierska-Gądek, Józefa, et al.
Publicado: (2007)

Tubulohelical membrane arrays: From the initial observation to the elucidation of nanophysical properties and cellular function
por: Reipert, Siegfried, et al.
Publicado: (2010)

Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme
por: Węsierska-Gądek, Józefa, et al.
Publicado: (2009)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014)

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
por: Bowman, K J, et al.
Publicado: (2001)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

MRN, CtIP, and BRCA1 mediate repair of topoisomerase II–DNA adducts
por: Aparicio, Tomas, et al.
Publicado: (2016)

BRCA1-BARD1 regulates transcription through modulating topoisomerase IIβ
por: Bunch, Heeyoun, et al.
Publicado: (2021)

Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells
por: More, Piyush, et al.
Publicado: (2019)

Utilizing Genome-Wide mRNA Profiling to Identify the Cytotoxic Chemotherapeutic Mechanism of Triazoloacridone C-1305 as Direct Microtubule Stabilization
por: Króliczewski, Jarosław, et al.
Publicado: (2020)

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

1305. Application of Standard Antibiotic Use Criteria to Evaluate Inpatient Antibiotic Use
por: Campion, Maureen, et al.
Publicado: (2018)

Synthesis and photobiological applications of naphthalimide–benzothiazole conjugates: cytotoxicity and topoisomerase IIα inhibition
por: Singh, Iqubal, et al.
Publicado: (2021)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
por: Das, Benu Brata, et al.
Publicado: (2014)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305()
por: Potęga, Agnieszka, et al.
Publicado: (2020)

1305. Use of a Clinical Pharmacist to Reduce Inpatient ART (Antiretroviral Therapy) Errors
por: Mitchner, DeMaurian, et al.
Publicado: (2019)

Facile Synthesis of Some Coumarin Derivatives and Their Cytotoxicity through VEGFR2 and Topoisomerase II Inhibition
por: Gomaa, Mohamed S., et al.
Publicado: (2022)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
por: Flörkemeier, Inken, et al.
Publicado: (2022)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
por: Ding, Xia, et al.
Publicado: (2016)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Computational screening of chalcones acting against topoisomerase IIα and their cytotoxicity towards cancer cell lines
por: Sangpheak, Kanyani, et al.
Publicado: (2018)

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
por: Kozuki, Toshiyuki, et al.
Publicado: (2017)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Localization of topoisomerase II in mitotic chromosomes
Publicado: (1985)

Topoisomerase II has to work late
por: Leslie, Mitch
Publicado: (2014)

Diversity and Functions of Type II Topoisomerases
por: Sutormin, D. A., et al.
Publicado: (2021)

Chromatinization Modulates Topoisomerase II Processivity
por: Lee, Jaeyoon, et al.
Publicado: (2023)

Chromatinization modulates topoisomerase II processivity
por: Lee, Jaeyoon, et al.
Publicado: (2023)

Natural Products as Topoisomerase II Poisons: Effects of Thymoquinone on DNA Cleavage Mediated by Human Topoisomerase IIα
por: Ashley, Rachel E., et al.
Publicado: (2014)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_demip0nc5th79fpbq1l21q9rg0